Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Solid Tumor|HER-2 Protein Overexpression
Interventions: BIOLOGICAL: ACTR T Cell Product|DRUG: Trastuzumab
Sponsor: Cogent Biosciences, Inc.